Rimantadine Therapy of Influenza A Infection in Mice

AUTOR(ES)

Rabinovich, Sergio

RESUMO

Eighty per cent of mice infected with a mouse-adapted strain of influenza virus died within 3 to 8 days after infection. Rimantadine given at maximum protective doses reduced mortality to 10%. This protection is dose related and can be demonstrated with doses from 4.5 to 24 mg per kg per day. Significant survival rates are shown by delaying treatment as long as 48 hr after infection. Lungs of treated mice have significantly less virus than those of controls at 24, 48, and 72 hr after infection. Antibody production as measured by hemagglutination inhibition is not different in treated and controlled mice. These results indicate that rimantadine is an effective prophylactic and therapeutic agent and that its activity is associated with decreased viral titers.

Documentos Relacionados

• Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults.
• Treatment of Influenza Infection of Mice by Using Rimantadine Hydrochlorides by the Aerosol and Intraperitoneal Routes
• Activity of Amantadine, Rimantadine, and Ribavirin Against Swine Influenza in Mice and Squirrel Monkeys
• Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection.
• Inhibition of influenza virus uncoating by rimantadine hydrochloride.